Skip to main content

Advertisement

Table 8 Cilengitide Pharmacokinetic Data

From: A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

Parameter (unit) n Geomean Min Max
Cmax (ng/mL) 11 61163 50100 85500
tmax (h) 11 1* 1 1.25
AUC0-t (ng/mL*h) 11 182069 128234 334829
AUC0- (ng/mL*h) 10 183968 134307 243990
λz (1/h) 10 0.230 0.155 0.278
t1/2 (h) 10 3.0 2.5 4.5
CL (mL/min/m2) 10 54.2 41.0 72.5
Vss (mL/m2) 10 12100 8299 16384
  1. Data are pharmacokinetic parameters of Cilengitide one hour after an intravenous infusion.
  2. *Median is given.
  3. Abbreviations are: n, number; Geomean, geometric mean; Min, minimum; Max, maximum; Cmax, the observed maximum plasma concentration; tmax, time to reach Cmax; AUC, area under the curve; λz, apparent first-order rate constant; t1/2, apparent terminal half-life associated with negative terminal slope; CL, total body clearance of drug from plasma; Vss, volume of distribution at steady state.